Eric Towler Email & Phone Number

Washington, DC, US

Rockville, Maryland, US

1. Establish PM way of working to produce single version of the truth2. Communicate at all level of company regarding project and portfolio status3. Lead core teams toward program objectives4. Manage contractual negotiations, execution, establishment of POs and invoice proecssing as well as any other obligations with vendors/collaborators

Using 30 years of end-to-end project management/leadership experience in drug development to provide ad hoc guidance to investors and biotech.Contact me @eric.m.towler@gmail.com for your short-/long-term needs

Norwood, Massachusetts, US

• Led the Product Development Team (PDT), ensuring excellent communication between functional SMEs within the PDT
• Provided contemporaneous/accurate/effective reporting of team progress to Senior Management
• Provided operational/strategic expertise input to Integrated Product Development Plans
• Worked closely with vendors and Finance to ensure accurate budgets/forecast
• Established new enterprise-level best-practice PM operations as lead for PMO

Cambridge, Cambridgeshire, GB

• Helped to integrate Alexion into AstraZeneca as the AZ Rare Disease unit
• Led cross-functional drug development teams to achieve key development, regulatory and commercial milestones
• Specific projects of note were danicopan and vemircopan
• Drove strategy development and lead new opportunities through governance approvals

Cambridge, Cambridgeshire, GB

• Led cross-functional drug development teams to achieve key development, regulatory and commercial milestones
• Accomplishments of note are 1) 2022 approval of both Imfinzi + tremelimumab in 1st line HCC; and 2) Imfinzi in 1st line BTC
• Drove strategy development and led new opportunities through governance approvals
• Championed best-practices, drove PM efficiency through leadership/influence of global team members and staff

Rockville, Maryland, US

• Managed program/project team(s) for Partner or Development Company development programs
• Delivered overall program/project timelines and budget, including managing service providers/subcontractors
• Assisted in the development and provision of training and related forums, including PM staff
• Advised senior management staff on project-related issues.

Raleigh, NC, US

• Provided PM and Operations Leadership for R&D drug development programs according to the needs of the organization; oversaw international programs in US, EU, and Israel
• Directly co-led the development of the serine protease inhibitor (upamostat) for oncology and IBS, RHB-204 for NTM infection (bronchiectasis) and RHB-104 for MAP infection diagnostic
• Contract negotiation with vendors, CROs and academic collaborators
• Oversaw basic research at academic centers, institutes, and contract research organizations

Larkspur, California, US

• Assisted managing directors and CEO in day-to-day analysis of investment opportunities

Lawrence Township, NJ, US

• Acted as matrix leader directly supervising experienced drug Project Managers and managing a portfolio governance committee overseeing projects from discovery to lifecycle management
• Acted as member of the department leadership team, setting policy and providing procedural oversight.

Melbourne, Victoria, AU

• Led the entire recombinant coagulation portfolio, guided leaders of Core Project Teams (CPT) to insure the successful delivery of global, cross-functional projects of strategic importance to CSL’s product portfolio
• Accomplishments of note: led submission and approval of rIX-FP (Idelvion™) in December 2014 and rVIII-SingleChain (Afstyla™) in 2015
• Represented the portfolio and CPTs at the Project Governance Committees and senior management advisory committee

Basking Ridge, NJ, US

• Acted as Lead Global PM in Oncology: one Phase II Integrated Project Team (DR5 Ab agonist, PDAC), one Integrated Strategy Team (IST) with responsibility for 4-5 pre-POC projects (NCEs and biologics).
• Led teams through strategic and tactical considerations in consideration of both the scientific data and commercialization needs of company.
• Led generation/update of Target Product Profile and Development Plan

Rahway, New Jersey, US

• Oversaw entire late-stage D&O portfolio; 25 NCEs, 15 unique targets.
• Lead PM for life-cycle management of JanuviaTM, JanumetTM and all related sitagliptin products (Janumet XR, Juvisync)
• Developed registration plan for both Janumet XRTM and JuvisyncTM with team leader

Leverkusen, North Rhine-Westphalia, DE

• Preclinical Project Manager/Leader for the gene-to-screen pipeline as part of the alliance with Millennium Pharma to discover novel genomic drug targets for oncology
• Led evaluation/execution of 100 projects per year by approximately 20 scientists, starting from committee approval and ending with delivery of characterized target/HTS assay

Bethesda, MD, US

• Evaluated the HERV-K protease as a potential model/mechanism for HIV-1 protease drug resistance
• Established and executed high-throughput screens of the NCI natural compound library for retroviral and oncology drug targets such as HIV-1 integrase and Creatine Kinase B

Brentford, Middlesex, GB

• Led multidisciplinary research efforts to investigate structure-activity relations of HIV-1 protease inhibitors and the molecular basis for drug resistance, and role of the Human Endogenous retrovirus
• Developed a novel E. coli expression/screening system

Ph.D., Biochemistry And Molecular Biology

B.S/B.A, Chemistry/Spanish (Math Minor)

General Studies-Part Of Study Abroad Program

Puebla, Mexico Summer Program